お勉強308:CAR-Tと外照射の組み合わせ

https://medical.nikkeibp.co.jp/leaf/mem/pub/search/cancer/news/202210/577017.html

再発・難治性DLBCLへのTisa-Celの有効性はがんの体積とCAR-T細胞投与前の病気の状態で予測できる可能性【日本血液学会2022】

CAR-Tに限らずICIでも、「腫瘍量を減らす」
という意味でRTの意義はあると思っています。

というところでASTRO2022にて

https://twitter.com/OmranSaifi/status/1585048760325136387

Oral #1 ✅ Comprehensive salvage RT for limited relapsed post-CART NHL improves overall survival, freedom from subsequent progression and event @ASTRO_org #ASTRO22 @HoppeBrad @TheColonelGray @wgbreen @MKD_BMT @MayoCancerCare @MayoFL_RORes @MayoRadOnc @MayoRegMed @MayoClinic pic.twitter.com/LlTAY4fr3r

— Omran Saifi, MD (@OmranSaifi) October 25, 2022

https://twitter.com/OmranSaifi/status/1585301411012939776

Oral #2 ✅ Bridging RT followed by CART is associated with improved local control compared to salvage RT post CART.
Should we be more proactive and offer RT early on as a bridging strategy to benefit from a synergistic RT+CART effect?#ASTRO22 @ASTRO_org @MayoCancerCare pic.twitter.com/r3wMWHvpd6

— Omran Saifi, MD (@OmranSaifi) October 26, 2022

CAR-T前にRTやった方がよさそう。
残っている場合はサルベージでRTもよさそう。